Management Team


Michael W. Nall | President & Chief Executive Officer

Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010.

From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems.

Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).

We selected Mr. Nall to serve on our board of directors due to his experience in the cancer diagnostics business, his expertise in the commercialization of products and services such as ours, his background in reimbursement and operations and his status as our chief executive officer and president.

Tim Kennedy | Chief Financial Officer and SVP of Operations

Mr. Kennedy brings to Biocept more than 30 years of financial and operational leadership experience, including over 25 years in the clinical diagnostics industry. From 2013 to July 2016, Mr. Kennedy served as Chief Financial Officer of Millennium Health, a privately held leading urine drug testing and pharmacogenetics laboratory company. From 2008 to 2012, Mr. Kennedy was Chief Financial Officer and General Manager of PLUS Diagnostics, a urology, gastroenterology and oncology lab. During his tenure at PLUS Diagnostics, the company was transformed from a small regional lab into a national anatomic pathology leader, culminating in a sale to Miraca Life Sciences, which then became the largest independent pathology company in the United States. From 1997 to 2008, Mr. Kennedy held an ownership position in Diagnostic Imaging Management, a multi-site imaging company that expanded from 12 to 33 free-standing centers across the United States. From 1988 to 1997, he held a number of management positions, including Head of Finance, with National Health Laboratories, the predecessor to LabCorp. In his role as Head of Finance, he was instrumental in completing over 50 acquisitions as well as the merger with Roche Biomedical Labs to form LabCorp in 1995. Mr. Kennedy serves on the Board of Directors for MyCircle Health, a data services company that helps patients with chronic health conditions measure, evaluate, control and communicate daily test results to their healthcare providers. Mr. Kennedy holds a bachelor’s degree in Business – Accounting/Information Technology from Keane University.


Lyle Arnold, Ph.D. | Senior Vice-President of Research & Development, Chief Scientific Officer

Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. Dr. Arnold recently founded Aegea Biotechnologies to acquire, develop, and commercialize, next generation nucleic acid technologies. Dr. Arnold also serves on the board of directors of Asuragen, a rapidly emerging biotechnology company in Austin, Texas as well as on the board of Aegea. Previously he was VP, Research at Gen-Probe from September 2003 to October 2009.

He has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder), where he was President and Chief Scientific Officer from October 2001 to September 2003. In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 36 issued U.S. patents and more than 140 issued and pending patents worldwide. He is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies core to Gen-Probe assays that have generated more than $5B in product revenue. In addition, he has authored more than 50 scientific publications.

He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.


Veena Singh, MD | Senior Vice President and Senior Medical Director

Dr. Singh brings years of laboratory diagnostics experience and a deep personal interest in blood-based biomarker testing. Prior to joining Biocept, Dr. Singh led the clinical laboratory team as the Medical Director at the molecular oncology diagnostics company bioTheranostics Inc. Her expertise in validating and launching assays in a CLIA lab setting, along with extensive knowledge of developmental stage biomarkers, serve as a major catalyst for Biocept’s continuing expansion of its offerings.

During Dr. Singh’s tenure at bioTheranostics Inc., the clinical laboratory’s test menu underwent significant expansion to incorporate assays in solid tumor molecular analysis utilizing multiple methodologies and platforms including Next-Generation Sequencing, RT-PCR, IHC and FISH. In addition, she brings a wealth of experience in the fields of regulatory agency compliance and reimbursement (FDA, IVDMIA and Companion Diagnostics).

Dr. Singh completed a Molecular Genetic Pathology fellowship at Cedars-Sinai Medical Center in Los Angeles and an Anatomic and Clinical pathology residency at the University of California, San Diego. Dr. Singh is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology. She received her medical degree from the University of Transkei in South Africa and is a Fellow of the College of American Pathologists and the American College of Medical Genetics.

David Moskowitz | VP of Strategy and Corporate Communications

Mr. Moskowitz coordinates the Company’s Investor Communications and Public Relations activities, and plays a key role in developing and driving Biocept’s value creation strategy. Most recently, he was Vice President, Investor Relations at Trovagene, a molecular diagnostics company. He is recognized as a leading equity research analyst, with more-than 16 years of Wall Street experience covering large-cap pharmaceutical, specialty pharmaceutical, biotechnology, generic drug, and molecular diagnostics companies. Mr. Moskowitz has held Director of Research positions at both Caris & Co. and Madison Williams & Co., and was Head of Healthcare Research at Friedman Billings Ramsey. He also held analyst positions at Roth Capital Partners, UBS Warburg, and Standard & Poor’s. In 2011, Mr. Moskowitz received the StarMine Analyst Award as the top stock picker among U.S. Biotechnology Analysts. In addition to his tenure as an equity research analyst, Mr. Moskowitz has performed strategic advisory work for many emerging biopharmaceutical and molecular diagnostics companies. He earned his BS in Pharmacy from Rutgers University, and his MBA in Finance and Pharmaceutical Industry Studies at Fairleigh Dickinson University.


Bret Gustafson | Business Development Director

Mr. Gustafson brings to Biocept over 17 years of experience in the Oncology and Hematology space. He recently came from Life Technologies where he was a Business Development Lead. His primary focus was driving the molecular bioinformatics business with key partners in the pharmaceutical and biotechnology industries, as well as academic institutions around the world. Prior to Life Technologies, he worked at Clarient, a GE Healthcare company, Oncotech, Precision Therapeutics, and Nabi. He is the Commercial Leader for Biocep’ts international, academic, pharmaceutical, and biotech collaborations. Mr. Gustafson received his B.S in Marketing from The University of Tennessee, at Chattanooga.


Amy McNeal | Senior Director, Reimbursement Strategies

Ms. McNeal has more than 20 years of experience in the diagnostic laboratory industry where she has held leadership roles in both sales and business development. During the past eight years, she has focused on developing and implementing reimbursement strategies and managed care contracting. Prior to Biocept she was with Clarient, a GE Healthcare Company, where she was Manager of the North American Managed Care unit. She was responsible for growing diagnostic services sales and reimbursement through contract agreements with national and regional managed care organizations, independent physician associations, and other payor groups. Prior to Clarient, Ms. McNeal was Executive Director of Sales and Contracting at Pathology, Inc., a specialty women’s health laboratory. She has held various positions at the both Quest Diagnostics and LabCorp. Ms. McNeal holds an MBA from Pepperdine University, Malibu, California and a Bachelor’s degree from Cal State, San Bernardino.


Cory Cairns | National Sales Director

Mr. Cairns brings 15 years of cancer diagnostics experience to Biocept. He most recently served as Sales Director at Integrated Diagnostics, and has held previous leadership positions with multiple companies in the diagnostics industry, including LabCorp, US Labs and Pathwork Diagnostics. Mr. Cairns leads Biocept’s US Sales and Customer Service teams, and is passionate about leadership and motivation, with prior experience as a personal coach. He graduated from Emporia State University with a degree in Business Administration.